GlaxoSmithKline and CVS sign deal to bring Shingles vaccine to “thousands of pharmacies”
GlaxoSmithKline (GSK) thinks that Shingrix, its new Shingles vaccine, is a growth booster. At least, that is the message that CEO Emma Walmsley has been pushing, naming it as one of the group’s best bets for expansion. That looks increasingly probable this month, as the company has signed an agreement with pharmacy chain CVS to supply the immunization across the U.S.
GSK’s share price has edged up by 4% so far this year
SOURCE: Yahoo Finance
CVS is America’s “leading retail pharmacy” and will be responsible for stocking Shingrix in over 9.800 locations in the country. Kevin Hourican, the group’s executive vice president of pharmacy services, made the following comment in a press release, talking the treatment up:
"Vaccination is key to preventing shingles and CVS Pharmacy is pleased to be able to provide patients with convenient access to this new and more effective vaccine. Our pharmacists can help patients determine if Shingrix is right for them and can vaccinate patients at times and locations that work for their busy schedules."
The deal comes hot on the heals of another agreement, this time between GSK and Albertsons, which will see Shingrix rolled out to another 4,900 locations in the country.
Luke Miels, GSK’s president of global pharmaceuticals, made released the following statement:
"Our focus is now getting all of the ducks in a row so that when a patient walks into the pharmacy and asks for the vaccine, it’s in stock, it’s reimbursed, and the healthcare provider knows how to give it. I’m pleased to say we’re advancing this process of negotiating access with commercial and Part D plans and in parallel we’re beginning to stock pharmacies and educate healthcare providers."
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.